TrialSignal
Clinical trial intelligence report
Phase Ib Clinical Study of BCMA-Targeted Chimeric Antigen Receptor T-Cell Injection (CART-BCMA) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT07458659-Jul 28, 2026
NCT ID
NCT07458659
Status
NOT_YET_RECRUITING
Phase
EARLY_PHASE1
Sponsor
Chulalongkorn University
Executive brief
Investment-Ready Snapshot
Phase Ib Clinical Study of BCMA-Targeted Chimeric Antigen Receptor T-Cell Injection (CART-BCMA) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma is a EARLY_PHASE1 clinical asset sponsored by Chulalongkorn University in Relapsed/Refractory Multiple Myeloma (MM). SEO and diligence focus: Chimeric Antigen Receptor T Cells (CAR-T), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07458659
Indication
Relapsed/Refractory Multiple Myeloma (MM)
Modality
cell therapy
Target
Chimeric Antigen Receptor T Cells (CAR-T)
Intervention
Chimeric Antigen Receptor T Cells (CAR-T)
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.